Bolt Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The reverse merger makes Prana’s pipeline the primary development focus, supported by $120 million in upfront financing and up to $60 million more from warrants. PRA-216 readouts are expected from Q2 2027, with pivotal trials targeted for early 2028.
Fiscal Year 2025
-
BDC-3042 demonstrated strong safety and early efficacy in phase I, especially in refractory NSCLC, with a confirmed partial response and ongoing stable disease. BDC-4182's trial is open, targeting a broader Claudin 18.2 market, and partnering discussions for BDC-3042 are progressing.
Fiscal Year 2024
-
The presentation highlighted a robust pipeline with two proprietary immunotherapy programs, strong financials supporting operations through mid-2026, and fully funded collaborations. Next-generation ISACs show enhanced efficacy and safety, with key clinical milestones expected in 2025.
-
The ISAC platform shows promise for durable tumor responses, with next-gen programs targeting broader tumor types and lower antigen expression. Key clinical data from BDC-3042 and BDC-4182 are expected in the next year, supported by strong partnerships and a cash runway to mid-2026.